<DOC>
	<DOCNO>NCT02402166</DOCNO>
	<brief_summary>The purpose study gain initial safety , tolerability , pharmacokinetic , efficacy information SPD489 preschool child 4-5 year old diagnose ADHD . Generating data provide data use SPD489 preschool ADHD population .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic , Efficacy Study SPD489 Preschool Children With Attention-deficit/Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>1 . Subject male female age 45 year inclusive time consent . Only recruit male subject December 2015 2 . Subject 's parent LAR must provide signature informed consent , must documentation assent ( applicable ) subject accordance ICH GCP Guideline E6 ( 1996 ) applicable regulation , complete studyrelated procedure . 3 . Subject parent/LAR willing able comply test requirement define protocol , include oversight morning dosing . Specifically , parent/LAR available daily dispense dose investigational product study duration . 4 . Subject must meet DSMIVTR criterion primary diagnosis ADHD ( subtypes ) base detailed psychiatric evaluation conduct sponsorapproved clinician 5 . Subject ADHDRSIV Preschool Version total score ≥93rd percentile Baseline Visit ( Visit 0 ) . For boy , score ≥32 . For girl , score ≥24 . 6 . Subject CGIS score ≥4 Baseline Visit ( Visit 0 ) . 7 . Subject Peabody Picture Vocabulary Test , Fourth Edition standard score ≥70 Screening Visit ( Visit 1 ) . 8 . Subject undergone adequate course nonpharmacological treatment base investigator judgment subject severe enough condition consider enrollment without undergo prior nonpharmacological treatment base investigator judgment . 9 . Subject , opinion investigator , participate structured group activity ( e.g. , preschool , sport , Sunday school ) ass symptom impairment set outside home . 10 . Subject live parent/LAR ≥6 month . 1 . Subject require anticipates need take medication CNS effect affect performance , sedate antihistamine decongestant sympathomimetics , take monoamine oxidase inhibitor . Stable use bronchodilator inhaler exclusionary . 2 . Subject take another investigational product take part clinical study within 30 day prior Screening Visit ( Visit 1 ) . 3 . Subject well control his/her current ADHD medication acceptable tolerability . 4 . Subject concurrent chronic acute illness ( severe allergic rhinitis infectious process require antibiotic ) , disability , condition might confound result safety assessment conduct study might increase risk subject . Similarly , subject exclude additional condition ( ) , investigator 's opinion , would prohibit subject completing study would best interest subject . The additional condition would include significant illness unstable medical condition could lead difficulty comply protocol . Mild , stable asthma exclusionary . 5 . Subject fail fully respond , base investigator judgment , previously administer adequate course amphetamine therapy . 6 . Subject document allergy , hypersensitivity , intolerance amphetamine excipients investigational product . 7 . Subject know family history sudden cardiac death ventricular arrhythmia . 8 . Subject blood pressure measurement ≥95th percentile age , sex , height Screening Visit ( Visit 1 ) Baseline Visit ( Visit 0 ) . 9 . Subject known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , serious cardiac problem place increased vulnerability sympathomimetic effect stimulant drug . 10 . Subject clinically significant electrocardiogram Screening Visit ( Visit 1 ) Baseline Visit ( Visit 0 ) clinically significant laboratory abnormality Screening Visit ( Visit 1 ) base investigator judgment . 11 . Subject current abnormal thyroid function , define abnormal thyroid stimulate hormone thyroxine Screening Visit ( Visit 1 ) . Treatment stable dose thyroid medication least 3 month permit . 12 . Subject current diagnosis adjustment disorder , autism , psychosis , bipolar disorder . 13 . Subject currently consider risk suicide opinion investigator , previously make suicide attempt , currently demonstrate active suicidal ideation . Subjects intermittent passive suicidal ideation necessarily exclude , base assessment investigator . 14 . Subject height ≤5th percentile age sex Screening Visit ( Visit 1 ) . 15 . Subject weight ≤5th percentile age sex Screening Visit ( Visit 1 ) . 16 . Subject history seizure ( infantile febrile seizure ) current diagnosis Tourette 's disorder . 17 . Subject chronic current tic disorder judge investigator exclusionary . 18 . Subject take medication exclude .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>